Skip to main content

Trastuzumab and Alcohol/Food Interactions

There is 1 alcohol/food/lifestyle interaction with trastuzumab.

Moderate

High Blood Pressure (Hypertension)

Moderate Potential Hazard, Moderate plausibility

HER2 inhibitors - CHF

Decreases in left ventricular ejection fraction (LVEF) have been reported with agents that block HER2 activity. Patients who have received prior anthracyclines, those who received anthracycline after stopping therapy with agents that block HER2 activity, or patients who received prior radiotherapy to the chest area may be at higher risk of decreased LVEF. Therapy with these agents should be administered cautiously in patients with a previous history of heart conditions. Evaluate cardiac function before, during, and upon completion of treatment. Withhold or discontinue therapy with agents that block HER2 activity as appropriate, and for a confirmed clinically significant decrease in left ventricular function, or if the LVEF has not improved or has declined further. It is recommended to monitor overall cardiac function and LVEF by echocardiogram or MUGA scan as appropriate.

References

  1. "Product Information. Herceptin (trastuzumab)." Genentech PROD (2001):
  2. "Product Information. Tykerb (lapatinib)." Novartis Pharmaceuticals (2007):
  3. "Product Information. Perjeta (pertuzumab)." Genentech (2012):
  4. "Product Information. Kadcyla (ado-trastuzumab emtansine)." Genentech (2022):
  5. "Product Information. Margenza (margetuximab)." Almirall (2021):
View all 5 references

Trastuzumab drug interactions

There are 177 drug interactions with trastuzumab.

Trastuzumab disease interactions

There are 4 disease interactions with trastuzumab which include:

Report options

Loading...
QR code containing a link to this page

Drug Interaction Classification

These classifications are only a guideline. The relevance of a particular drug interaction to a specific individual is difficult to determine. Always consult your healthcare provider before starting or stopping any medication.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No interaction information available.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Medical Disclaimer